Skip to content

Study of the Effects of Transcutaneous Vagus Nerve Stimulation on Cancer Patients' Fatigue and Quality of Life After Radiotherapy or Chemotherapy

Study of the Effects of Transcutaneous Vagus Nerve Stimulation on Cancer Patients' Fatigue and Quality of Life After Radiotherapy or Chemotherapy

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047527
Enrollment
Unknown
Registered
2021-06-20
Start date
2021-06-21
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

intervention group:transcutaneous vagaus nerve stimulation
sham intervention group:transcutaneous vagaus nerve stimulation at the tragus without current

Sponsors

The First Affiliated Hospital of the Air Force Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 65 years; 2.Participants diagnosed with nasopharyngeal cancer, esophageal cancer,lung cancer, or cervical cancer, suitable for radical radiotherapy or chemotherapy; 3.Participants diagnosed with rectal cancer, suitable for neoadjuvant radiotherapy or chemotherapy before surgery; 4.Participants diagnosed with breast cancer, suitable for adjuvant radiotherapy after surgery; 5.Eastern Cooperative Oncology Group (ECOG) physical condition score: 0~1 point.

Exclusion criteria

Exclusion criteria: 1.Participants with organic brain lesions (cerebral hemorrhage, large-area cerebral infarction, encephalitis, epilepsy, etc.); 2.Participants with peptic ulcer, arrhythmia, or cardiac corrected QT interval> 450ms; 3.Participants who have slow breathing (less than 10 breaths per minute); 4.Participants who are or have been diagnosed with other major diseases (coronary heart disease, pulmonary heart disease, etc.); 5.Participants who are currently or have been diagnosed with mental disorders other than major depressive disorder; 6.Participants who are or have participated in vagus nerve or transcranial electrical stimulation treatment for less than 3 months; 7.Participants who are not suitable for vagus nerve stimulation treatment; 8.Participants who refuse to sign informed consent.

Design outcomes

Primary

MeasureTime frame
patient's overall fatigue score;

Secondary

MeasureTime frame
the difference between the patient's overall fatigue score and baseline score;quality of life scale;the depression and anxiety level of participants;hot flashes score;absolute value, proportion and reduction rate of lymphocytes and their subsets compared with baseline;Levels of c-type reactive protein, tumor necrosis factor -a, interleukin-6 and other inflammatory factors;the level of sleep quality;

Countries

China

Contacts

Public ContactZhao Li'na

The First Affiliated Hospital of the Air Force Medical University (Xijing Hospital)

zhaolinazln@outlook.com+86 13572553455

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026